#Switzerland #Hamilton Company #GlucoSense #bioprocess analytics #Bonaduz

Hamilton Unveils GlucoSense: A New Era in Glucose Monitoring

In a groundbreaking development, Hamilton has introduced GlucoSense, a pioneering technology set to transform bioprocess analytics through real-time, in situ glucose measurement in mammalian cell cultures. This unique reusable sensor stands out by directly integrating within bioreactors, offering continuous data to ensure precise control over cell metabolism and product quality.

Addressing a Critical Need

Bioprocessing specialists have long sought reliable methods to monitor glucose levels without interrupting workflows, often relying on offline and periodic measurements that miss transient fluctuations. GlucoSense fills this analytical void by delivering real-time monitoring capabilities that streamline glucose management, paralleling the intuitive measurement methods already established for pH and dissolved oxygen.

The device is launched specifically for use with wetted autoclave processes, fitting well in glass or benchtop bioreactors commonly employed during R&D stages and early process development phases. Hamilton is committed to advancing this technology, with plans to introduce a steam-in-place (SIP) compatible version for steel bioreactors—ideal for clinical and commercial use—by the end of 2026.

Giovanni Campolongo, Senior Market Segment Manager at Hamilton, emphasized the significance of this innovation: "With GlucoSense, we’re providing customers real-time access to critical metrics in mammalian cell culture, simplifying processes previously burdened with calibration and complexity. Our roadmap supports users from research and development through to Good Manufacturing Practice (GMP) manufacturing."

A Solution that Makes a Difference

Glucose status plays a vital role in influencing key elements of cell metabolism, such as lactate production and overall cellular viability. As it’s a significant determinant of product quality, any oversight could result in inconsistent outcomes. GlucoSense's continuous in situ measurements prevent these blind spots, enabling scientists to respond promptly to glucose deviations.

The sensor's design highlights a compact optical probe that does not require fragile fiber optics, ensuring durability and efficient sterilization, aligning with numerous autoclave cycles. Utilizing mid-infrared ATR spectroscopy tuned for specific glucose absorption features, GlucoSense circumvents the complex chemometric modeling seen in other spectroscopic platforms. Instead, it employs a straightforward semi-permeable membrane for sample collection, securing reliable data while preventing cell contamination.

Integrated Arc technology also enhances ease of use, storing calibration constants and diagnostics directly within the sensor head, enabling effortless digital integration and GMP-ready documentation.

Performance Validation and Collaborative Efforts

Data supporting GlucoSense's reliability emerged from comprehensive internal tests and an invaluable partnership with the University of Applied Sciences and Arts Northwestern Switzerland (FHNW). This collaboration involved rigorous testing under conditions resembling real-world bioprocess scenarios.

In fed-batch settings, GlucoSense consistently produced stable glucose measurements over 130 hours, demonstrating remarkable alignment with offline reference readings. Similarly, in high-density perfusion tests over three weeks, the sensor maintained accuracy while requiring minimal recalibrations.

Campolongo noted, "The validation work with FHNW was pivotal in proving GlucoSense's accuracy and stability. It provides our users a solution free from the usual maintenance or consumables issues associated with older technologies."

The Future of Bioprocessing Awaits

With GlucoSense, Hamilton addresses one of the primary gaps within upstream processing analytics while gearing up for the future of bioproduction. This sensor-based tool not only enhances operational efficiency but also facilitates smoother transitions to automated operations enhanced by AI and other digital technologies.

Hamilton's commitment to developing a SIP-compatible version reinforces their vision of a connected, intelligent, and data-driven bioprocessing landscape as the industry shifts toward continuous processing. GlucoSense equips manufacturers with the critical nutrient data necessary for unlocking innovations in biologics production.

As one of the leading global manufacturers, Hamilton continues to support the scientific community with cutting-edge products designed for reliability, performance, and flexibility across various applications in life sciences, clinical diagnostics, biotechnology, and biopharma industries. Their dedication to high standards is evident in their ISO 9001 certifications and advanced manufacturing facilities located in Reno, Nevada, and Bonaduz, Switzerland.

For more information about GlucoSense and Hamilton's product offerings, visit Hamilton Company.